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Foreword | This paper investigates the 
frequency of intravenous drug use in a 
cohort of people who inject drugs, and 
the decline in use over time. It provides an 
important indication of the effectiveness 
of current interventions at reducing the 
consumption of illicit drugs. Comparisons 
are made between the injection frequency 
of participants on or off Opioids 
Substitution Therapy (OST), and 
according to the settings in which drugs 
are most frequently purchased and used 
(eg street, house).
This research found an overall movement 
away from street based drug purchasing 
and drug use, towards more activity in 
private settings. This has important 
implications for the harms experienced by 
people who inject drugs. Intravenous drug 
use was persistent, with only slow 
declines observed in the frequency of the 
cohort’s overall use. Lower injection 
frequency was associated with use in 
private rather than public locations as well 
as the uptake of OST.
Additional work is needed to understand 
how this change in setting is affected by 
and also affects current interventions, and 
whether it can be used to help further 
reduce injecting drug use.
Adam Tomison  
Director
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People who inject drugs (PWID) typically do so over considerable periods, in some cases 
up to 20 or 30 years, before stopping for a sustained period (Oppenheimer et al. 1994, 
Henderson et al. 2002). One aim of drug law enforcement and harm reduction interventions 
is to reduce the negative health and social consequences experienced by PWID and society 
during the period in which an individual injects drugs, which is sometimes called their 
‘injecting career’ (Ministerial Council on Drug Strategy 2011). The term ‘maturing-out’ has 
long been applied to people who use drugs but then outgrow their habits (Winick 1962), 
whether with the aid of services or of their own accord. Little is known about whether PWID 
in Australia mature out of drug use in the longer term, and how this is achieved. Prospective 
cohort studies such as the Melbourne Injecting Drug User Cohort Study (MIX) (Horyniak et 
al. 2013) offer an insight into these patterns. This paper considers some of the changes that 
have been observed in the MIX cohort of PWID over time.
This study also focuses on how the frequency of injecting drug use has changed over time 
within the MIX cohort. The frequency of a cohort’s drug use reflects the group’s market 
demand, and is likely to indicate the risks to which cohort members are exposed (eg blood-
borne viruses, police involvement). Without major drug market or policy changes, shifts in 
the frequency of injecting drug use indicate how use persists over time, making it possible 
to assess the extent to which PWID mature-out. 
Data collected since 2008 on the frequency of drug use of MIX participants indicate that 
most consider heroin as their drug of choice. Between 2008 and 2014, the price, purity and 
availability of heroin remained fairly stable (Cogger et al. 2014, Scott et al. 2015b). There 
were also few policy changes of any major impact during this period. Buprenorphine-based 
Opioid Substitution Therapy (OST) underwent a program shift from the use of Subutex to 
Suboxone (NPS RADAR 2011, Australian Institute of Health and Welfare 2014), however 
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the effect of this on OST uptake is unknown 
and total OST use in Victoria has been 
largely stable since 2008 (Cogger et al. 
2014). The relative stability of the heroin 
market and related drug policies provides 
an opportunity to assess how patterns 
of drug use evolve under current policy 
interventions. Treatment programs such 
as OST are designed to reduce use and 
harms (Ward, Hall et al. 1999).   In Australia 
OST is provided in two forms, either with 
methadone or buprenorphine, both being 
demonstrably effective (Mattick et al. 2003, 
Mattick et al. 2014). This study examined 
correlations between OST enrolment and 
frequency of drug use in the cohort over time. 
PWID are known to cycle through periods 
of increased and lower use before long 
term cessation (Kimber et al. 2010). The 
recruitment mechanisms of cohort studies 
can target individuals currently at the high 
end of their cycle. Regression to the mean 
is a phenomenon that occurs when initial 
observations are systematically biased, 
and later ones are not (Barnett et al. 2005). 
This may cause apparent changes in 
characteristics that are simply convergence 
towards their unbiased values, and the 
potential of this is featured in the data.
The settings of drug deals (eg street, 
house) and those in which drugs are 
most likely to be used are reported in 
MIX, enabling them to be analysed to 
understand their evolution and the interplay 
between purchase and use location type, 
frequency of drug use, and the maturing-
out phenomenon. This information can 
inform when and where interventions may 
be best pursued (Decker 2005). 
Figure 1 Purchase location types and use location types across Melbourne
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Methods
Data source
This study used data on drug purchases 
and drug use obtained from MIX. MIX is 
a prospective cohort study of 688 PWID 
who were recruited into the study between 
April 2008 and January 2010. Another 69 
participants, members of a different cohort 
known as Networks II, were rolled into the 
study in 2011. MIX participants are young 
compared with those in most studies of 
injecting drug use in Australia. Individuals 
were eligible for the study if they were 
between 18 and 30 years old and had 
injected either heroin or methamphetamine 
at least six times over the previous six 
months. Experienced fieldworkers interview 
participants face-to-face every 12 months 
or so, and obtain detailed information on 
up to three recent purchases of heroin, 
methamphetamine, benzodiazepines and 
other opioids, as well as on the frequency 
of injecting a range of drugs. Median 
dates for baseline and the first three 
follow-up interview waves undertaken to 
date are July 2009 (interquartile range 
or IQR, March 2009–November 2009), 
August 2010 (IQR April 2010–April 2011), 
September 2011 (IQR April 2011−February 
2012) and August 2012 (IQR March 2012–
December 2012). Further details on MIX 
can be found elsewhere (Horyniak et al. 
2013, Scott et al. 2015a).
Relevant interview questions relating 
to each purchase are: the type of 
location where the drug was purchased, 
categorised as house (including shared 
accommodation and public housing), 
street, mobile dealer or other (Scott et al. 
2015a); and the location type where the 
drug was used, categorised as house, 
street, public toilet, car or other. For each 
interview a participant was considered 
to use more often in private if most of 
their purchases (maximum of 12, 3 for 
each of heroin, methamphetamine, 
benzodiazepine and other opioids) were 
used in houses. They were considered to 
use more often in public if most of their 
purchases were used in public locations 
(streets, public toilets or cars). Less than 
five percent of interviews reported equal 
locations of use and so were excluded 
from this classification. A new variable 
‘total injections in the last week’ was 
created by adding the number of injections 
in the last week reported for each of the 
drugs: heroin, methadone, buprenorphine, 
Suboxone, morphine, oxycodone, other 
opiates, powder methamphetamine, 
base methamphetamine, crystal 
methamphetamine, prescription 
stimulants, cocaine, hallucinogens, 
ecstasy, benzodiazepines, antipsychotics, 
antidepressants and other drugs. 
Most injections were of either heroin 
or methamphetamine, which together 
constituted 77 percent of reported 
injections over all interviews.
Participants reported if they were currently 
on OST or not. At baseline interviews, 
38 percent of MIX participants (n=285) 
were enrolled in OST. Compared with 
participants not on the therapy, those on 
OST were more likely to be slightly older 
(median age 29 vs 27), female (44% of 
females vs 34% of males were enrolled, 
χ2(1)=6.45, p<0.05), have had a longer 
injecting career (mean 11.7, 95%CI 
11.1−12.3 years vs 9.4, 95%CI 8.9−9.8 
years) and have been to prison (42% of 
participants who had been to prison were 
enrolled in OST vs 31% of those who had 
not, χ2(1)=9.57, p<0.01). Participants on, 
and not on, OST were similar in terms of 
current living circumstances, employment 
status, income, country of birth and 
language spoken.
Purchase and use location types
All purchases of heroin, methamphetamine, 
benzodiazepines and other pharmaceutical 
opioids were pooled across individuals for 
interviews occurring on each day between 
1 January 2009 and 1 March 2014. A rolling 
60-day period was used to determine the 
percentage of drugs bought and used in 
each location type. So, for the data point 
plotted for 30 June averages are based on 
all individuals interviewed between 1 May 
and 30 June  inclusive.
The percentage of purchases and use 
occurring in each setting was calculated 
for each of the first four interview waves  by 
OST status, using all available data from 
April 2008 to March 2014.
For each interview wave, distributions 
of total injections in the last week were 
generated. Among participants reporting 
recently injecting, the mean injection 
frequency was calculated for each interview 
wave and used to estimate the annual 
decline in average frequency of use, based 
on median interview dates. Due to a tail of 
high-frequency injectors these distributions 
were highly right-skewed, meaning that 
trends among high frequency injectors may 
have disproportional or misleading effects 
on overall changes, particularly if they were 
greatly different from trends among low 
frequency injectors. To measure the extent 
of the skew at each interview wave, the 
contribution of the most frequently injecting 
20% of participants was analysed. The 
percentage of the cohorts’ total injections 
attributable to this high use group was 
calculated.
To measure changes to the overall 
frequency of participants’ drug use, 
interviews between January 2009 and 
December 2013 were pooled into six month 
periods, and for each period the mean ‘total 
injections in the last week’ was calculated 
and plotted over time.
The total number of injections reported in 
the last week was categorised as either 
zero, 1–2 times, 3–7 times, 8–14 times 
or 15 or more times. For each interview 
wave, the percentage of participants who 
reported injecting at each categorised 
frequency was calculated. Separate 
column charts were generated showing 
these percentages after stratifying by OST 
status and by whether a participant used 
most in private or public locations.
To explore the effects of participants lost 
to follow-up on the difference in OST 
status, a comparison was made between 
the frequency of injecting and percentage 
enrolment in OST of participants with fewer 
than four interviews (measured at their final 
interview) and those of participants with 
four or more interviews (measured at their 
fourth interview).
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Results
Purchase and use location types
Most drugs were bought in houses. 
The percentage of purchases in houses 
increased over time, while that of street 
purchases fell. House, street and mobile 
dealer categories made up 46 percent, 
28 percent and 25 percent of purchase 
location types reported in 2009 respectively. 
By contrast, house, street and mobile dealer 
categories made up 59 percent, 15 percent 
and 26 percent of purchase location 
types reported in 2013 respectively. This 
difference between years was statistically 
significant (χ2(2)=62.4, p<0.001). 
The most reported drug use also occurred 
in houses. The percentage of use sessions 
occurring in houses increased over time, 
while that of street use fell. House, street, 
public toilet and car categories made up 
43, 27, 10 and 15 percent of use location 
types reported in 2009 respectively. By 
contrast, house, street, public toilet and 
car categories made up 58, 13, 11 and 
15 percent of use location types reported 
in 2013 respectively, and this difference 
between years was statistically significant 
(χ2(3)=77.5, p<0.001).
Purchase and use location types by 
OST status
Participants on OST purchased and used 
in different types of locations than those 
who were not on OST. Participants on 
OST reported fewer street purchases 
and more purchases in houses. Those on 
OST reported 17 percent and 56 percent 
of purchases on the street or in houses 
over the first four interviews respectively, 
while participants not on OST reported 
26 percent and 51 percent of purchases 
on the street or in houses respectively. 
This difference was statistically significant 
(χ2(3)=84.6, p<0.001). Participants on OST 
also reported that fewer purchases were 
used on the street. Participants on OST 
reported that 17 percent and 54 percent 
of purchases were used on the street or 
in houses over the first four interviews 
respectively, while participants not on OST 
reported that 24 percent and 47 percent 
of purchases were used on the street or 
in houses respectively. This difference was 
statistically significant (χ2(4)=71.2, p<0.001). 
Mobile dealer purchases, and use in cars or 
public toilets did not vary with OST status.
Distributions of injection frequency
The distributions of total injections per week 
were right-skewed, and shifted towards 
less use with each interview wave (Figure 3, 
left). Participants who reported recent use 
had mean weekly injection frequencies of 
10.3 (95%CI 9.3–11.1), 8.5 (7.5–9.5), 8.3 
(7.1–9.4) and 8.0 (6.8–9.3) at baseline and 
the first three follow-up interview waves 
respectively. The top 20 percent of most 
frequent injectors accounted for 39, 30, 30 
and 26 percent of all reported injections 
in the baseline and first three follow-
up interview waves respectively. This 
indicates that distributions of use became 
less skewed over time, most notably 
between baseline and the first follow-up 
interview waves.
The cohort’s overall frequency of use 
(including those not injecting) declined 
between 2009 and mid-2010 before 
experiencing small variations (Figure 3, 
right). This is consistent with the changes 
observed in average injection frequency 
between interview waves.
If the initial decline between the baseline 
and follow-up interviews is removed (due 
to the likely effects of regression to the 
mean), then these results imply that those 
who reported use reduced their frequency 
of injecting by 5.9 percent between the 
follow up one and three interviews. This 
is about three percent a year, based on 
median interview dates. This decline was 
not statistically significant.
Categorised injection frequency, by 
OST status and use location
Overall, participants on OST injected around 
35 percent less frequently than those not 
on OST. Among participants who reported 
injecting, the mean weekly frequency was 
11.0 (95%CI 10.2−11.8) for those who were 
not on OST, compared with 7.2 (6.6–7.9) for 
those who were. 
Figure 2 Purchase location types and use location types by interview OST status
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When categorised, injection frequencies 
differed by OST status and most common 
use location (Figure 4). Participants on 
OST were less likely to be high-frequency 
injectors and more likely to either abstain 
from injecting or inject once or twice a week 
(χ2(4)=76.6, p<0.001). This was also true 
for participants who used most of their 
drugs in private, rather than public locations 
(χ2(4)=13.6, p<0.01). Injection frequency 
declined across interviews for participants 
both on and off OST, and for participants 
who used the most in either public or 
private locations.
The differences apparent in Figure 4 may 
also be an underestimate, as participants 
not included in all four interview wave data 
were more likely to be high-frequency 
injectors and not on OST. Participants with 
fewer than four interviews had an average 
injection frequency of 8.7 (95%CI 7.2−10.1) 
and a 40 percent enrolment in OST in their 
last interview, while participants with four or 
more interviews had an average injection 
frequency of 5.1 (95%CI 4.2−6.2) and a 
60 percent enrolment in OST (χ2(2)=26.2, 
p<0.001) in their fourth interview.
Discussion
The study shows a very slow decline in 
the frequency of injecting drug use among 
PWID. In particular, after an initial decrease 
up to mid-2010, Figure 3 (right) does not 
show any further significant changes in mean 
injection frequency. Although distributions 
of use frequency (Figure 3, left and Figure 
4) continued to shift towards less frequent 
use after follow-up one (approximately 
corresponding with mid-2010), the additional 
declines were small. After removing these 
initial effects, it is estimated that PWID 
reduce their injecting at a rate of about three 
percent a year. The fact that frequency of 
use declines so slowly indicates that injecting 
drug use requires sustained long-term 
interventions. Once recruited into use, the 
decline among PWID to eventual maturing-
out is long, and the current levels and types 
of interventions appear inadequate at curbing 
the demand from existing PWID. 
The mean injection frequency of participants 
on OST was 35 percent lower than for those 
not on OST, indicating that access to OST 
was associated with a reduction in demand 
for illicit drugs. The reduction in injecting 
frequency when enrolled in OST is consistent 
with the findings of numerous previous 
studies (eg Gowing et al. 2011). Further, 
as participants lost to follow-up were more 
likely to be high-frequency injectors and not 
on OST, the 35 percent reduction observed 
is likely to be an underestimate and the 
injection frequency among those not on OST 
may be understated.
These data show an overall movement away 
from street-based drug purchasing and 
drug use towards more activity in private 
settings. This trend was observed almost 
equally among participants on and off OST. 
Since participants on OST were using more 
in private settings than participants off OST 
to begin with, increasing coverage of OST 
within the cohort (38%, 53%, 59% and 60% 
of participants were on OST for the first 
four interview waves respectively) may have 
enhanced this trend when considered for the 
combined cohort; that is, made the overall 
shift appear greater than the individual shifts 
within OST and off OST subgroups.
The reduction in street-based market activity 
may represent a positive outcome for the 
MIX cohort, as use in private locations was 
associated with a lower injection frequency. 
This may also be a positive outcome for 
social amenity, which has been seen to 
improve when injecting drug use declines 
more generally (Day et al. 2004). However, 
without knowing the injecting habits of 
those new to injecting drug use, this study is 
limited in determining broader levels of social 
amenity. Despite this change in setting, risks 
to individuals still exist, such as overdosing 
that goes with use in more private locations 
(Darke & Zador 1996). Innovative education 
and outreach strategies are needed to 
minimise these risks. 
Figure 3 Average ‘total injections in the last week’
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These shifts in purchase and use settings 
have further implications for drug policy, 
as purchases occurring in private settings 
represent the largest and growing market 
component. This is true both for percentage 
of deals and their size, as it has been 
observed that purchases in houses in 
Melbourne are larger (in dollar value) 
than purchases made in public locations 
(Scott et al. 2015a). In general, a better 
understanding and increased focus on these 
types of transactions is needed.
Estimating the decay rate of use in this 
study had two limitations. First, PWID are 
known to cycle through periods of increased 
and lower use. It is plausible that the MIX 
recruitment requirement of ‘injecting either 
heroin or methamphetamine at least six 
times over the previous six months’ or, more 
generally, a lack of desire to join during 
a period of cessation, may have biased 
recruitment towards participants in high use 
periods of their injecting cycles. If baseline 
interviews were biased towards higher use, 
regression to the mean would explain why 
changes between baseline and follow-up 
one interviews were greater than changes 
observed between other interviews. In 
particular, the initial decrease in use shown 
in Figure 3 (right) appears consistent with 
this phenomenon. If this effect lasted 
beyond follow-up one, frequency of 
use may decline even more slowly than 
observed. Cyclic frequency of use patterns 
among PWID may also have affected the 
OST findings. It is plausible that self-initiated 
enrolment in OST was biased towards 
PWID who had already reduced their use. 
Causal links cannot be drawn between OST 
enrolment and reduced injection frequency. 
Second, while the heroin market 
remained fairly stable during this 
period, methamphetamine dramatically 
declined in purity-adjusted price and 
became increasingly available (Scott 
et al. 2015b). However, as 64 percent 
of the cohort reported heroin as their 
drug of choice, against only 12 percent 
reporting methamphetamine, changes to 
the methamphetamine market are only 
expected to have affected a minority of 
participants (Scott et al. 2015c).
Conclusion
This study examines some of the ways 
in which injecting drug use evolves over 
time in a cohort of PWID. It shows shifts 
in the settings in which cohort members 
reported buying and using their drugs. 
These shifts have important implications 
for the harms experienced by PWID, and 
the wider community. Overall, declines in 
use were slow. However, use in private 
rather than public locations and the uptake 
of OST were both associated with lower 
reported injection frequencies. Further work 
is needed to understand how this change 
in setting affects current interventions, 
and whether it can be used to help further 
reduce harms related to injecting drug use.
Figure 4 Total injections in the last week by OST status and use most in private and most in public
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